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Available online 6 February 2016Thrombus formation leading to vaso-occlusive events is a major cause of death, and involves complex interac-
tions between coagulation, fibrinolytic and innate immune systems. Leukocyte recruitment is a key step,
mediated partly by chemotactic complement activation factors C3a and C5a. However, mechanisms mediating
C3a/C5a generation during thrombosis have not been studied. In a murine venous thrombosis model, levels of
thrombin–antithrombin complexes poorly correlated with C3a and C5a, excluding a central role for thrombin
in C3a/C5a production. However, clot weight strongly correlatedwith C5a, suggesting processes triggered during
thrombosis promote C5a generation. Since thrombosis elicitsfibrinolysis,we hypothesized that plasmin activates
C5 during thrombosis. In vitro, the catalytic efficiency of plasmin-mediated C5a generation greatly exceeded that
of thrombin or factor Xa, but was similar to the recognized complement C5 convertases. Plasmin-activated C5
yielded a functional membrane attack complex (MAC). In an arterial thrombosis model, plasminogen activator
administration increased C5a levels. Overall, these findings suggest plasmin bridges thrombosis and the immune
response by liberating C5a and inducing MAC assembly. These new insights may lead to the development of
strategies to limit thrombus formation and/or enhance resolution.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Fibrinolysis1. Introduction
The coagulation system and innate immunity are coordinately
activated and highly integrated during venous and arterial thrombus
formation and progression (von Bruhl et al., 2012; Engelmann and
Massberg, 2013; Fuchs et al., 2012). Vascular endothelial activation or
damage causes release of ultralarge von Willebrand factor (VWF) and
P-selectin from Weibel-Palade bodies, and local activation of comple-
ment with liberation of anaphylatoxic and chemotactic factors C3a
and C5a. These pathways cooperate to trigger platelet, neutrophil, and
monocyte recruitment and activation (von Bruhl et al., 2012). The
locally accumulated cells release proteases, reactive oxygen species,F, von Willebrand factor; R751,
vena cava; VFKck, Val-Phe-Lys-
lketone; FeCl3, ferric chloride;
hil extracellular traps; PAR1,
emoattracant protein-1; IL-8,
306-2350 Health SciencesMall,
nada.
. This is an open access article underand nucleosomes, which provide a scaffold for aggregating platelets
and red blood cells and further promote coagulation and fibrin formation
(Fuchs et al., 2012). Several complement factors, including C3, C4, C3a,
C5a and factor H are incorporated into the thrombus, where theymodu-
late thrombus stability and the inflammatory process (Distelmaier et al.,
2009; Howes et al., 2012). The fibrinolytic system and plasmin-mediated
proteolysis are also intimately coupled to the axis of thrombus develop-
ment and inflammation by controlling fibrin degradation, activation of
matrix metalloproteinases, infiltration of monocytes/macrophages and
other immunemediators, vessel wall remodeling, and ultimately throm-
bus resolution (Wakefield et al., 2008).
The mechanisms by which leukocytes are recruited early in throm-
bus formation and later during thrombus extension or resolution, are
poorly understood.However, C5a, themost potent chemotactic comple-
ment activation fragment, is released following proteolytic cleavage of
C5 and is considered a critical determinant of neutrophil recruitment
and activation in thrombosis (Distelmaier et al., 2009; Salmon et al.,
2002; Pierangeli et al., 2005). Moreover, terminal complement pathway
complexes formed as C5 is activated, have multiple procoagulant prop-
erties (Langer et al., 2013; Hamilton et al., 1990). Thus, there is interest
in understanding how C5a and the other major complement-derivedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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gies may be designed to prevent thrombosis.
Complement activation typically proceeds via three pathways —
classical, lectin and alternative—which converge to form C3 convertases
that proteolyse C3 into C3b with release of C3a (Ricklin et al., 2010). As
complement activation exceeds a threshold, and the density of C3b
increases, the specificity of the convertase shifts from C3 to C5. The
resultant C5 convertases — C3bBbC3b for the alternative pathway and
C4b2aC3b for the classical/lectin pathway— efficiently cleave C5 at argi-
nine 751 (R751), liberating C5a and generating C5b, the initiating factor
for assembly of the lytic C5b-9 membrane attack complex (MAC).
Although the C3/C5 convertases are well-recognized for their capacity
to cleave C3 and C5, other serine proteases reportedly also exhibit
convertase activity (Huber-Lang et al., 2006; Amara et al., 2010; Wiggins
et al., 1981). Notably, thrombin was implicated in providing a “new
pathway” to activate complement by cleaving C5 in a C3-independent
manner, thereby bypassing the bona fide C5 convertases (Huber-Lang
et al., 2006). However, C5 is a relatively poor substrate for thrombin
cleavage at R751 (Krisinger et al., 2012), raising questions as to its impor-
tance in contributing to C5a generation during thrombus formation
in vivo. We therefore explored the mechanisms by which C3a and C5a
are generated using biochemical approaches and in vivo models of
venous and arterial thrombosis.
2. Materials and Methods
2.1. Materials
Human complement C3a and C5a were measured using Quidel
MicroVue C3a Plus or C5a ELISA kits (Cedarlane Laboratories, Burlington,
Ontario). Murine thrombin–antithrombin (TAT) levels were measured
using Enzygnost TAT micro ELISA (Siemens, Munich, Germany).
Human complement proteins C3 and C5 were obtained from Comple-
ment Technology, Inc. (Tyler, TX) and human hemostatic enzymes
(plasmin, factor Xa and thrombin) were from Haematologic Technolo-
gies, Inc. (Essex Junction, VT).
2.2. ELISAs to Measure C3a and C5a
Murine complement C5a levels were determined using the mouse
complement component C5a duoset and accompanying standard from
R&D systems (catalog #DY2150; Minneapolis, MN). An ELISA for
murine complement C3a was established using a murine C3a standard
and antibodies from BD Biosciences (Mississauga, Canada). The capture
rat monoclonal anti-mouse C3a antibody (catalog # 55820, clone: I87-
1162) was coated overnight onto 96-well plates in 100 μL of PBS at a
concentration of 2 μg/mL. Wells were washed ×3 with wash buffer
(R&D catalog #WA126) followed by blocking for 2 h with 300 μl of
reagent diluent (R&D systems catalog #DY995). Plasma samples in
duplicate were diluted 1/50 and 1/125 in sample diluent to a final
volume of 100 μl and incubated for 2 h. After 3 washes, 100 μl of the
biotinylated detection monoclonal rat anti-mouse C3a antibody (clone
I87-419, catalog #55821) 0.5 μg/mL in reagent diluent was incubated
for 1 h. Wells were washed ×4 and incubated for 20 min at room
temperature with 100 μl of streptavidin-biotinylated horseradish per-
oxidase (1:3000), followed by 2 washes, and development with the
substrate solution containing o-phenylenediamine using a plate reader
set to 450 nm. A standard curve was generated with purified murine
C3a (catalog # 558618). The sensitivity range of the assay was 0.1 nM
to 2.5 nM. Intra-assay and inter-assay precision was 8–10%.
2.3. Animal Models
All experiments with animals were approved by the University of
North Carolina at Chapel Hill Institutional Animal Care andUse Commit-
tees. The mice (C57Bl/6) were male and between 6 and 8 weeks of age.The number of animals for eachmodel was determined based on previ-
ous work that showed a broad range of TAT levels in the respective
models (Machlus et al., 2011a, 2011b). On each day of the experiments,
animals were randomly assigned to receive the stated treatment or to
be used for baseline measurements. Quantification of biomarkers was
performed in a blinded fashion wherein an experimenter, different
from the one who performed the procedures on the animals, carried
out the ELISAs on coded samples that were only de-coded after results
had been generated.
2.4. Murine model of Venous Thrombosis
The inferior vena cava (IVC) stasis model was performed as previ-
ously described (Aleman et al., 2013). Briefly, mice were anesthetized
with 1·5–2% isoflurane in oxygen and human prothrombin (to 300%,
final, mouse plus human prothrombin) or vehicle was infused via tail
vein injection. Prothrombin was infused to give a broader range of
thrombin generation and clot weight. Following sterile laparotomy,
the intestines were exteriorized, the IVC was dissected bluntly, and
side branches were ligated with 8–0 prolene suture and lumbar
branches closed by cautery. The IVC was separated from the aorta by
blunt dissection and completely ligated with 8–0 prolene suture. After
replacing the intestines, the muscle layer was closed with 5–0 vicryl
suture and skin closed with 8–0 prolene suture and skin glue. Mice re-
covered with analgesia (buprenorphine, 0·05 mg/kg subcutaneous).
After 12 h, blood was drawn from the IVC above the ligation site into
3.2% sodium citrate and processed to platelet-poor plasma by centrifu-
gation at 5000 ×g for 10 min. Thrombi were collected and weighed.
Plasmas were stored at−80 °C for analysis of TAT, C3a and C5a levels
by a person that was blinded to the treatment group. Two samples
showing hemolysis were excluded.
2.5. In Vitro Generation of C3a or C5a by Hemostatic Enzymes
The relative efficiency, time course, and rate of complement cleavage
by plasmin, factor Xa or thrombin were determined using a series of
assays. Briefly, complement C3 (20 μM) or C5 (2 μM) was incubated
with 100 nM plasmin or 250 nM factor Xa or thrombin. Reactions
were quenched at various time points and C3a or C5a levels were quan-
tified by ELISA. To determine the relative efficiency of cleavage, 2 μM of
C5 was incubated with 100 nM of plasmin, factor Xa or thrombin at
37 °C. After 10 min the reaction was quenched with the appropriate
chloromethylketone (Val-Phe-Lys-chloromethylketone (VFKck) for
plasmin and Phe-Pro-Arg-chloromethylketone (PPAck) for factor Xa
and thrombin). In similar experiments, aliquots of the reaction mixture
were sub-sampled into chloromethylketones at various time points to
determine the time courses of C3 and C5 cleavages by plasmin, factor
Xa and thrombin. The kinetics of C5a generation were determined by
incubating 0–3 μM of C5 with 100 nM of plasmin at 37 °C. Reactions
were quenched after 1 min and C5a levels were quantified by ELISA.
Similar experiments substituting factor Xa or thrombin for plasmin
were conducted, but the amount of C5a generated in these assays over
30 min (for factor Xa) or 1 h (for thrombin) was below the limit of
detection for the assay.
C5a generation occurring during clot formation and degradation
was assessed in vitro by incubating physiological concentrations
of fibrinogen (9 μM), plasminogen (2 μM), antiplasmin (1 μM)
and C5 (400 nM) at 37 °C. High (1 μM) or low (10 nM) concentra-
tions of thrombin were added to induce clot formation and 10 nM
of tPA was used to induce plasminogen activation and clot lysis.
The tPA concentration chosen resulted in complete clot lysis in
30 min. At the end of the 30-minute incubation period, enzymes
were quenched with PPAck and VFKck, the sample centrifuged and
supernatant or sample stored at −80 °C for quantification of C5a
levels. Background C5a signal when PPAck/VFKck was added at
t = 0 were subtracted.
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Complement factors C5 (400 nM) and C6 (500 nM) were incubated
with 100 nMof plasmin or 250 nMof factor Xa or thrombin. Parallel reac-
tions were quenched over timewith an appropriate chloromethylketone.
The amount of functional C5b,6 generated was subsequently quantified
using a chicken erythrocyte hemolytic assay (Wat et al., 2014). Since plas-
min readily cleaves C5,we also incubated 500nMof C5b,6with 100nMof
plasmin to determine if C5b,6 activity diminishes over time. In these ex-
periments, plasmin was quenched with VFKck.
2.7. Ferric Chloride Model of Arterial Thrombosis
Mice were anesthetized with 1·5–2% isoflurane in oxygen. Ferric
chloride injury to the carotid artery was performed as described
(Aleman et al., 2013). Briefly, the right common carotid artery was ex-
posed, dried, and treated with ferric chloride (7·5 or 10% on
0·5 × 1·0-mm filter paper) for 2 min. The artery was washed with
warm saline and bloodflowwas continuouslymonitored byDoppler ul-
trasonic flow probe (Indus Instruments). The time to vessel occlusion
was defined as the time between FeCl3 administration and lack of flow
for 60 s. Blood was sampled into citrate from the IVC 5 min after stable
vessel occlusion (defined as continuous occlusion for 1 min) or after
40 min if no occlusion occurred.
2.8. Thrombolysis Model
Thrombolysis was assessed in mice subjected to FeCl3 carotid artery
thrombosis. After 5 consecutive minutes of vessel occlusion, mice were
infused with Tenecteplase (5 mg/kg, generous gift of Genentech, CA)
through a saphenous vein intravenous catheter constructed of pulled
PE-10 tubing (Braintree Scientific, Braintree, MA) with a 3·0-mil
(0·076-mm diameter) cleaning wire (Hamilton Company, Reno NV)
placed into the lumen as a stylet, as described (Machlus et al., 2011a),
while continuously monitoring carotid blood flow. Blood was sampled
from the IVC 5 min after the return of blood flow or 30 min after
Tenecteplase infusion if the clot did not lyse.
2.9. Statistics
The relationships between prothrombotic and complement activa-
tion markers were assessed using Spearman rank correlation. C3a and
C5a levels were compared using t-tests or the Wilcoxon rank sum test
(Tenecteplase-treated versus untreated mice). P b 0·05 was considered
statistically significant.
3. Results
We studied the role of thrombin in complement activation using an
in vivomurine model of ligation (stasis)-induced IVC thrombosis (von
Bruhl et al., 2012; Aleman et al., 2013). Plasma levels of activation
markers of coagulation and complement were measured by ELISA. Base-
line TAT levels were 3·8 ± 4·0 ng/mL (n = 5), as previously reported
(Aleman et al., 2013). 24 h after IVC ligation, plasma TAT levels rose to
21·2 ± 11 ng/mL (mean ± SD, n = 6). Prothrombin was infused in
some mice to give a broader range of thrombin generation and clot
weight (Aleman et al., 2013) (Fig. 1 — open circles —mice infused with
prothrombin; solid circles — mice infused with vehicle). When pro-
thrombin was infused just prior to IVC ligation (Aleman et al., 2013),
TAT levels measured at 24 h were significantly higher (47·9 ±
19 ng/mL, n=8, p b 0·009). As expected, clot weights directly correlated
with TAT levels (r = 0·66, p b 0·01). Plasma levels of C5a and C3a in ve-
nous thrombosis were elevated as compared to baseline (unchallenged)
levels (C5a = 0·43 ± 0·15 nM; C3a b 0.1 nM; n= 6). Interestingly, cir-
culating levels of complement activationmarkers C3a and C5a correlated
poorly with TAT levels (Fig. 1a, b), suggesting that thrombin does notdirectly activate complement in this experimental model of venous
thrombosis. Notably, C5a also correlated poorly with C3a (Fig. 1c), sug-
gesting that C5a was generated to a large extent via C3/C5 convertase-
independent pathways. Furthermore, there was no relationship between
clot weight and C3a levels (Fig. 1d). There was, however, a strong direct
correlation between clot weight and C5a levels (Fig. 1e). Taken together,
these findings show that processes triggered during venous thrombosis
are associated with C5a generation, but suggest that thrombin is not
the major activator of C5 under these conditions.
To determine the potential mechanisms of C5a generation in vivo,
we used in vitro assays in purified systems to compare C5a generation
following cleavage of C5 by thrombin, factor Xa or plasmin. Plasmin
was considered a likely candidate of complement activation in the set-
ting of a fibrin clot because, 1) plasmin is known to cleave C5 to yield
chemotactically-active C5a in vitro (Amara et al., 2010), and 2) fibrin
is an essential cofactor for tissue-type plasminogen activator (tPA)-
mediated plasmin generation (Horrevoets et al., 1997).
Incubation of C3 or C5 with thrombin, factor Xa or plasmin revealed
that plasmin ismuchmore effective than thrombin or factor Xa in cleav-
ing C3 and C5 to generate C3a and C5a, respectively (Fig. 2a, b). Plasmin
more readily cleaved C5 than C3, with ~30% of C5 (~700 nM) being
converted to C5a, and only ~2% of C3 (~450 nM) cleaved to form intact
C3a. The low turnover of C3 by plasmin, thrombin and fXa precluded
further in vitro interrogation. The incomplete cleavage of C5 to C5a
under the conditions employed may reflect competitive inhibition by
an abundance of cleavage products (molecular weight N30–70 kDa)
that were detected following SDS-PAGE (not shown and (Barthel
et al., 2012)).We compared the efficiency of C5 cleavage by various con-
centrations (0–100 nM) of each of the three enzymes (Fig. 2c). During a
10-minute incubation period, plasmin generated substantially more
C5a than factor Xa or thrombin.
In kinetic assays, the rate of C5a generation by plasmin in-
creased linearly as the concentration of C5 increased (Fig. 2d).
The catalytic efficiency, inferred from the slope of the plot, was
2·3 ± 0·6 × 104 M−1 s−1 (Distelmaier et al., 2009). This is similar to
the published rate of C5 cleavage by the bona fide alternative pathway
C5 convertase and the soluble monomeric classical/lectin pathway C3/
C5 convertase (Rawal and Pangburn, 1998, 2001). This rate of C5 cleav-
age by plasmin is therefore consistent with the premise that plasmin
has a physiologically relevant role in generation of C5a.
Since plasmin is rarely, if ever, free in circulation, we next tested
whether plasmin is capable of generating C5a in the presence of physi-
ological concentrations of antiplasmin and fibrinogen, that when
converted to fibrin, binds plasminogen and plasmin with high affinity.
We first confirmed that even at very high concentrations, thrombin
generates almost undetectable amounts of C5a (Fig. 2e, conditions i,
ii). In the absence of plasminogen, tPA was incapable of cleaving C5
to yield C5a (Fig. 2e, condition iii). When C5 was incubated with tPA
and plasminogen in the presence of fibrin(ogen) (Fig. 2e, condition v),
readily detectable amounts of C5a were generated, and this occurred
even in the presence of physiological concentrations of antiplasmin
(condition iv). Absence of fibrinogen, a cofactor for tPA-mediated
conversion of plasminogen to plasmin, resulted in the generation of
measurable, but less, C5a than with fibrinogen (condition v versus vi).
Overall, the data confirm that in the presence of physiological concen-
trations of hemostatic proteins, C5a can be generated in a plasmin-
dependent manner.
Convertase-mediated release of C5a from C5 occurs in parallel with
generation of C5b that is required for MAC formation. Using a terminal
pathwayhemolytic assay (Wat et al., 2014),we showed that in the pres-
ence of excess C6, cleavage of C5 by factor Xa or plasmin yielded a C5b,6
complex that could assemble with C7, C8 and C9 to form a fully func-
tional lytic MAC. The efficiency of C5b,6 generation by plasmin, factor
Xa and thrombin mirrored that observed for C5a (Fig. 3a). Over
60 min, 100 nM of plasmin generated 3·0 ± 0.6 nM C5b,6, whereas
even 250 nM of factor Xa (which is ~2-fold higher than the plasma
Fig. 1. Coagulation and complement activation in venous thrombosis. Following stasis-induced thrombosis of the inferior vena cava (see Materials and Methods section), levels of
thrombin-antithrombin complexes (TAT), C3a, and C5a were measured by ELISA. C3a (a) and C5a (b) levels correlated poorly with TAT levels. C3a and C5a levels also poorly
correlated (c), implying the existence of C3-independent pathways to generate C5a. Clot weight poorly correlated with C3a (d), but strongly correlated with C5a (e). Each dot
represents a separate mouse, n = 14. Solid circles are untreated mice (infused with vehicle); open circles are mice that were infused with prothrombin to increase thrombin
generation (see Materials and Methods section). Correlation coefficients (r) with 95% confidence levels and p-values are indicated on each panel.
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Consistent with its inefficient cleavage of C5, thrombin (250 nM) did
not generate any detectable C5b,6. Thus, although plasmin can cleave
C5 at several sites (Barthel et al., 2012), exposure of C5b,6 to plasmin
for 1 h did not appreciably decrease the functionality of theMAC (Fig. 3b).
In view of these in vitro findings, we tested the association between
thrombin generation and complement activation in a second, indepen-
dent thrombosis/thrombolysismodel, and used thismodel to determine
whether C5 is activated by thrombolytic pathways in vivo. Using wild-
type mice with stable carotid artery thrombi induced by ferric chloride,
we first showed that 5 min after occlusion, TAT levels correlated poorly
with systemic levels of C3a and C5a (r = −0·36, p = 0·39 for C3a;
r =−0·05, p = 0·91 for C5a; n= 8), consistent with our observations
in the venous thrombosis model. To determine the impact ofplasminogen activation in this setting, we intravenously administered
the tPA analog Tenecteplase (n=8) intomice that had been challenged
with arterial occlusion and measured C3a and C5a 5 min after restora-
tion of blood flow, or 30 min after infusion if blood flow was not re-
stored (Fig. 4a, b). Of these, 3 mice did not re-perfuse and 5 mice did
re-perfuse. Regardless of outcome, all mice that received Tenecteplase
were included in the analysis. As compared to ferric chloride-
challenged mice that were not infused with Tenecteplase (n = 9),
Tenecteplase caused a significant (~2-fold) increase in C3a and C5a
levels. Notably, this increase is in line with published studies in a
small group of patients treated with recombinant tPA following acute
myocardial infarction (Bennett et al., 1987). Our finding that C5 could
not be cleaved by recombinant tPA (Fig. 2d, iii) makes it highly unlikely
that the elevated C5a levels were attributable to Tenecteplase-mediated
Fig. 2. Hemostatic enzymes generate C5a. a, b, c. In a purified system, plasmin (100 nM) (▴), factor Xa (250 nM) (•) or thrombin (250 nM) (■) was incubated with C3 or C5 for varying
periods of time and C3a (a) or C5a (b) wasmeasured by ELISA. Plasmin efficiently generated C3a (a) (inset is highermagnification to show relative initial rates of C3a generation) and C5a
(b) within 1 min, whereas factor Xa or thrombin took much longer to generate appreciable amounts of C3a or C5a. c. C5 (2 μM)was incubated for 10 min with varying concentrations of
each of the three enzymes, after which C5a levelsweremeasured by ELISA. Plasminwas significantlymore efficient at cleaving C5 than factor Xa or thrombin. d. The rate of C5a generation
by plasmin increased linearly as the concentration of C5 increased. The slope of the line implies that plasmin cleaves C5, generating C5a with a catalytic efficiency of 2.3 ±
0.6 × 104 M−1 s−1 (Distelmaier et al., 2009). e. Thrombin (10 nM, 1 μM; i, ii, respectively) or tPA (10 nM) (iii) did not generate significant levels of C5a from C5. Addition of
plasminogen (2 μM) to the system enabled plasmin generation and was associated with C5a generation in the absence (iv) or presence (v) of 1 μM of antiplasmin. Fibrinogen (9 μM)
(vi) is not essential for C5a generation when tPA, plasminogen and C5 are present, but it enhances C5a generation in the context of tPA induced plasminogen activation (v). The data
presented in a, b are a single representative experiment and the data for all other experiments (c–e) represent means ± SD for 3 replicates. n.d. = not detectable.
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in vitro that exposure of C5 to high concentrations of tPA (up to
200 nM) for 10 and 30 min, did not yield measurable amounts of C5a
(data not shown). Taken together, these data are consistent with a
direct effect of plasmin on complement activation during thrombosis.
4. Discussion
Thrombus formation leading to pathological vaso-occlusive events
(e.g. acute coronary syndrome, stroke, deep vein thrombosis and pul-
monary embolus) is a major cause of death worldwide (Mozaffarianet al., 2015; Raskob et al., 2014). Initiation, propagation, and resolution
of a thrombus rely on the recruitment of platelets and inflammatory
cells, and this is mediated partly by local release of the complement
activation factor C5a. C5a is a potent anaphylatoxic peptide, inducing a
range of pro-inflammatory and pro-thrombotic effects via its cognate
G-protein-coupled receptors, C5aR and C5L2. C5a activates platelets,
leukocytes and endothelial cells, upregulates expression of adhesion
molecules, induces secretion of pro-inflammatory and procoagulant
cytokines, promotes tissue factor expression by neutrophils and release
of tissue factor-containing microparticles, induces the formation of
neutrophil extracellular traps (NETs), and amplifies complement
Fig. 3. Hemostatic enzymes generate C5b,6. a. Cleavage of C5 by plasmin (▴), factor Xa (•), or thrombin (■) in the presence of excess C6, C7, C8 and C9, resulted in the generation of
functional C5b,6, measured by a terminal pathway erythrocyte hemolytic assay. Thrombin did not generate any measurable C5b,6 in this experimental system. b. The functional
integrity of C5b,6, measured by the terminal pathway hemolytic assay, did not decay appreciably over a 1-hour period when incubated with plasmin. The data presented represent
means ± SD for 3 replicates.
Fig. 4. Effects of plasminogen activator-mediated thrombolysis on C3a and C5a levels. a, b. Stable carotid artery thrombosis was induced in wild-type mice using the ferric chloridemodel
(seeMaterials andMethods section), afterwhich the plasminogen activator Tenecteplasewas administered intravenously as noted. C3a (a) and C5a (b) levelswere significantly increased
by Tenecteplase infusion. Each dot represents a separate mouse (n = 9 controls, n = 8 infused with Tenecteplase).
Fig. 5. Proposed contributions of plasmin-mediated C5 activation in thrombosis. During a. thrombus formation, progression, and b. resolution, fibrin deposition promotes plasmin
generation, which activates complement. The traditional complement activation pathways likely also participate (not shown). The effects of plasmin-mediated complement activation
on thrombus growth and resolution depend on the timing and localization of C5a generation, and assembly of the membrane attack complex (MAC). a. Thrombus formation:
Following endothelial cell activation/damage, C5 (and C3) is activated, generating C5a and C5b (1), the latter of which binds to C6–C9 to form the membrane-damaging, procoagulant
MAC. C5a is a potent chemoattractant for platelets and neutrophils (2) and activates cells to express monocyte chemoattractant protein-1 (MCP-1) and interleukin (IL)-8 (3). These
pathways cooperate to recruit and activate platelets, monocytes and neutrophils (4), with release of reactive oxygen species, proteases and nucleosomes, all of which enhance
thrombus formation (5). b. Thrombus resolution: As plasmin degrades fibrin into fibrin degradation products (FDPs) (6), it also generates C5a and C5b (1). C5a induces the release of
factors (e.g. MCP-1, IL-8) (3) that recruit macrophages and neutrophils (7), which promote clot resolution by augmenting plasmin generation (8), fibrin degradation, and phagocytic
clearance of clot-associated debris (9).
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2012). Given the current findings, we propose a model in which plas-
min, via liberation of C5a, contributes to leukocyte trafficking during
thrombus formation, propagation and/or resolution (Fig. 5). The precise
local contribution of C5a (and C3a) to thrombus formation and resolu-
tion, is difficult to ascertain, particularly since clearance of these pep-
tides is short and likely dynamically changes in this setting.
Nonetheless, with generation of C5a, terminal complement pathway
complexes form which also regulate coagulation. C5b-7 induces tissue
factor expression by monocytic cells (Langer et al., 2013), while the
MAC induces VWF and P-selectin secretion, platelet microparticle re-
lease, and endothelial cell and platelet membrane changes that favor
prothrombinase assembly and thrombin generation (Hamilton et al.,
1990; Wiedmer et al., 1986; Sims et al., 1988). Since C5 activation is as-
sociated with many disease states, including acute lung injury, arthritis,
sepsis (Huber-Lang et al., 2006; Kessel et al., 2014; Yan and Gao, 2012),
and thrombosis (Distelmaier et al., 2009; Cheung et al., 1994), the pres-
ent studies suggest that interventions at the level of plasmin may have
broad clinical utility.
From studies with mouse models (Huber-Lang et al., 2006; Hoth
et al., 2014; Khan et al., 2013; Auger et al., 2012; Zecher et al., 2014;
Borkowska et al., 2014), several groups have concluded that thrombin
is the major coagulation enzyme that generates C5a under pathologic
conditions. This role for thrombin was supported by observations that
thrombin generates C5 in vitro (Huber-Lang et al., 2006), and inhibition
of thrombin dampens severity of disease and reduces C5a levels in
murine models of disease (Huber-Lang et al., 2006; Hoth et al., 2014;
Khan et al., 2013; Auger et al., 2012; Zecher et al., 2014; Borkowska
et al., 2014). How do we reconcile these findings with the fact that the
residuesflanking theR751C5 convertase cleavage site necessary to gen-
erate C5a lack similarity to thrombin cleavage sites in all other classic
thrombin substrates (e.g., protein C, PAR1, fibrinogen, factor V, factor
VIII) (Krisinger et al., 2012), and that thrombin is an inefficient cutter
of C5 at that site (Krisinger et al., 2012)?
That thrombin participates in C5a generation during coagulation is
not challenged by the present findings. However, this reaction likely
does not occur via direct C5 cleavage. Indeed, in our experiments, with
thrombin concentrations that more closely approximate the dynamics
of thrombin generation in plasma and blood (Brummel et al., 2002;
Dielis et al., 2008), C5a could not be measured. Moreover, the C5T
product that is generated by thrombin-mediated cleavage of C5 at the
thrombin-sensitive R947 site (Krisinger et al., 2012), does not exhibit
C5a-like chemotactic/migration properties in vitro (data not shown).
The present studies are consistent with the concept that thrombin con-
tributes to C5a generation, but indirectly via plasmin-mediated events.
Thrombin is fundamentally important for the initiation of fibrinolysis
since it generates fibrin, an important cofactor for tPA-mediated plas-
min generation. Thrombin further amplifies plasmin generation by
inducing endothelial secretion of tPA and expression of urokinase-
type plasminogen activator (van den Eijnden-Schrauwen et al., 1995).
Given the relative kinetics of thrombin versus plasmin in generating
C5a, it is unlikely that thrombin, alone, generates C5a. Rather, our data
support the premise that, in combination with C5 convertase, plasmin
(and/or downstream proteolytic effectors of plasmin) is the major
mediator, and that the amount of thrombin only affects C5a levels inso-
far as thrombin affects the kinetics of fibrinolysis/plasmin generation.
The caveat to this premise is that very high thrombin concentrations
that may transiently accumulate during thrombus formation (Brummel-
Ziedins et al., 2005) could cleave C5 at R751 to generate C5a (Krisinger
et al., 2012). Interestingly, reports of a role for thrombin in generating
C5a come from studies with mice lacking C3 (Huber-Lang et al., 2006;
Khan et al., 2013; Auger et al., 2012; Borkowska et al., 2014). These
mice, for unexplained reasons, have elevated levels of prothrombin
(Huber-Lang et al., 2006) which can result in increased generation of
thrombin following activation of coagulation (Aleman et al., 2013; Kyrle
et al., 1998). It is reasonable to consider that the high thrombin levelsreached in C3-deficient mice might contribute to C5a generation. How-
ever, with excess thrombin and fibrin deposition, plasmin generation
would also be markedly increased, and plasmin would be significantly
favored over thrombin in generating C5a from C5. Indeed, this apparent
paradox of heightened plasmin generation with a larger thrombus is in
line with our observation that IVC clot weights strongly correlated with
C5a levels. By interfering with deposition of fibrin, a critical cofactor for
plasmin generation, thrombin inhibition would reduce C5a generation.
Overall, thrombin is important in C5a generation, but indirectly, via
enhanced production of plasmin. These findings are consistent with,
and indeed, extend previous in vitro studies inwhich high concentrations
of plasmin cleaved C5 (Amara et al., 2010). Attempts to measure murine
levels of plasma plasmin–antiplasmin complexes were confounded by a
lack of reliable assays. However, in vivo gain-of-function studies using
pharmacologic-intervention (Tenecteplase infusion), allow us to con-
clude that plasmin plays a physiologically relevant role in the generation
of C5a.
Although plasmin generation is increased acutely and to a lesser
extent, chronically, in patients with thrombotic disorders (Wada et al.,
1989), the role of plasmin in complement-mediated events during
thrombus formation, propagation, and resolution is unknown. Our
finding that plasmin drives C5a generation in mouse models of throm-
bosis exposes plasmin and/or its downstream effectors as potential
therapeutic targets for limiting production of procoagulant and pro-
inflammatory effectors. These insights are likely to be applicable to
thrombi in arteries and veins, in spite of the differences with regard to
etiology of these presentations. Indeed, and most notably, both presen-
tations involve activation of inflammatory pathways and liberation of
fibrinolytic activity in response to the thrombus (Engelmann and
Massberg, 2013; Wolberg et al., 2012). The impact of any intervention
would likely be dependent on its timing in relation to thrombus forma-
tion and resolution (Fig. 5). Thus, early dampening of C5a and MAC
assembly may thwart leukocyte accumulation and thrombus initiation
and propagation. Later interventions may hinder resolution of the clot,
but may also reduce long-term inflammatory sequelae of thrombosis,
such as occurs in post-thrombotic syndrome. Intuitively, administering
agents to suppress fibrinolysis during a thrombotic event at any stage
may be unappealing, and thus an optimal intervention strategy/agent
might preservefibrinolysiswhile restrictingC5 activation. Direct blocking
of C5 activation is highly efficacious in preventing complement-mediated
thrombosis in atypical hemolytic uremic syndrome and paroxysmal
nocturnal hemoglobinuria (Wong and Kavanagh, 2015). Similar suc-
cesses were not, however, observed for acute myocardial infarction
(APEX AMI Investigators et al., 2007), which might be due to the fact
that therapy was initiated early at presentation. The variable responses
in these reports underline the need for further study, using models that
represent different vascular disorders.Contributors
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